National Health Chengno Biotechnology

Beijing Guojian Chengno Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative T-cell receptor (TCR) engineered T-cell therapies for the treatment of solid tumors. Based in Beijing, the company utilizes a proprietary platform for the identification and validation of high-affinity TCRs targeting tumor-specific antigens and viral antigens. Its lead candidate is a TCR-T therapy designed to treat Hepatitis B Virus (HBV)-related hepatocellular carcinoma by targeting HBV-derived antigens expressed on malignant cells. In addition to its HBV program, the company is advancing a pipeline of therapies targeting neoantigens and shared tumor antigens like NY-ESO-1. Chengno Biotechnology aims to overcome the challenges of the immunosuppressive tumor microenvironment to provide effective treatments for patients with advanced cancers.